VJHemOnc Podcast
The Myeloma Sessions: Evolving management of myeloma & COVID-19
Aug 6, 2020
María-Victoria Mateos discusses evolving management of myeloma & COVID-19, including reducing infection risk, mortality rates of myeloma patients, immunity and thrombogenic potential of COVID-19, managing myeloma patients, repurposing myeloma drugs for COVID-19 treatment, and advancements in CAR-T and bi-specific therapies for multiple myeloma.
52:25
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Myeloma patients infected with COVID-19 in Spain had higher mortality rates, with predictors including age, gender, disease activity, renal impairment, and comorbidities.
- Recent conferences showcased promising advancements in myeloma treatment, with targeted therapies like CAR-T cell therapies and bispecific monoclonal antibodies demonstrating impressive efficacy, raising hopes for improved outcomes and prolonged survival.
Deep dives
Evolution of Strategies to Reduce Risk for Myeloma Patients during COVID-19
In Spain, the myeloma group launched recommendations to maintain disease control and minimize patient visits to hospitals, especially for young patients with active disease. Elderly patients with renal impairment were advised to stay at home and receive oral drug combinations. In New York, therapy was selectively used, trials were halted, and patients were managed with optimized infection control. Similar approaches were taken in Greece, where myeloma patients were tested for SARS-CoV-2 virus and treatments were adjusted based on patient characteristics and disease severity. Management strategies included low molecular weight heparin therapy and prioritizing disease control in patients infected with COVID-19.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
